Dendritic cells dictate the responsiveness to PD-L1 blockade in cancer

被引：0

作者：

Mayoux, M. ^{[1
]}

Roller, A. ^{[2
]}

Pulko, V ^{[1
]}

Chen, S. ^{[1
]}

Fransen, M. ^{[3
]}

Kowanetz, M. ^{[4
]}

Rommel, K. ^{[1
]}

Matos, I ^{[1
]}

Colombetti, S. ^{[1
]}

Belousov, A. ^{[5
]}

Karanikas, V ^{[1
]}

Hegde, P. ^{[4
]}

Chen, D. ^{[4
]}

Mellman, I ^{[4
]}

Umana, P. ^{[1
]}

Perro, M. ^{[1
]}

Ossendorp, F. ^{[3
]}

Klein, C. ^{[1
]}

Xu, W. ^{[1
]}

机构：

[1] Roche Innovat Ctr Zurich, Schlieren, Switzerland

[2] Roche Innovat Ctr Basel, Basel, Switzerland

[3] Leiden Univ, Med Ctr, Leiden, Netherlands

[4] Genentech Inc, San Francisco, CA USA

[5] Roche Innovat Ctr Munich, Penzberg, Germany

来源：

EUROPEAN JOURNAL OF IMMUNOLOGY | 2018年 / 48卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

T-40

引用

页码：22 / 23

页数：2

共 50 条

[41] PD-L1 Blockade for Cancer Treatment: MEDI4736
Ibrahim, Ramy
Stewart, Ross
Shalabi, Aiman
SEMINARS IN ONCOLOGY, 2015, 42 (03) : 474 - 483
[42] PD-L1 blockade for urothelial carcinoma
Kang, Josephine
Galluzzi, Lorenzo
ONCOIMMUNOLOGY, 2017, 6 (07):
[43] Increased PD-L1 Expression and PD-L1/CD86 Ratio on Dendritic Cells Were Associated With Impaired Dendritic Cells Function in HCV Infection
Shen, Tao
Chen, Xiangmei
Chen, Yu
Xu, Qiang
Lu, Fengmin
Liu, Shuang
JOURNAL OF MEDICAL VIROLOGY, 2010, 82 (07) : 1152 - 1159
[44] Toxicities Associated With PD-1/PD-L1 Blockade
Wang, Daniel Y.
Johnson, Douglas B.
Davis, Elizabeth J.
CANCER JOURNAL, 2018, 24 (01): : 36 - 40
[45] PD-1 and PD-L1 blockade in gastrointestinal malignancies
Lote, Hazel
Cafferkey, Catherine
Chau, Ian
CANCER TREATMENT REVIEWS, 2015, 41 (10) : 893 - 903
[46] Mechanisms of Resistance to PD-1 and PD-L1 Blockade
Nowicki, Theodore S.
Hu-Lieskovan, Siwen
Ribas, Antoni
CANCER JOURNAL, 2018, 24 (01): : 47 - 53
[47] The intracellular signalosome of PD-L1 in cancer cells
David Escors
María Gato-Cañas
Miren Zuazo
Hugo Arasanz
María Jesus García-Granda
Ruth Vera
Grazyna Kochan
Signal Transduction and Targeted Therapy, 3
[48] The intracellular signalosome of PD-L1 in cancer cells
Escors, David
Gato-Canas, Maria
Zuazo, Miren
Arasanz, Hugo
Jesus Garcia-Granda, Maria
Vera, Ruth
Kochan, Grazyna
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2018, 3
[49] Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells
Tu, Jingyao
Xu, Haoran
Ma, Li
Li, Chunya
Qin, Wan
Chen, Xinyi
Yi, Ming
Sun, Li
Liu, Bo
Yuan, Xianglin
THERANOSTICS, 2022, 12 (02): : 747 - 766
[50] Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Iwai, Y
Ishida, M
Tanaka, Y
Okazaki, T
Honjo, T
Minato, N
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (19) : 12293 - 12297

← 1 2 3 4 5 →